Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Intratumoral TLR4 agonist therapy elicits antigen-specific T cell clonal expansion in metastatic leiomyosarcoma: a case series.

Frontiers in oncology·2026

Same author

How I treat soft tissue sarcomas.

Future oncology (London, England)·2026

Same author

Real-World Data on the Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer.

World journal of oncology·2026

Same author

Pre-diagnostic route reported by patients with sarcoma from the Netherlands, the UK, Australia and New Zealand: early detection challenges for general practitioners - an international observational cohort study.

BMJ open·2026

Same author

In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Comparative Analysis of CEM and Breast MRI: A Retrospective Study.

Journal of surgical oncology·2026

Same journal

The Treatment Efficacy for Patients Undergoing Combined Transanal-Transabdominal Endoscopic Resection of Rectal Anastomosis Stenosis.

Journal of surgical oncology·2026

Same journal

"It Depends on the Situation": Variability in How Surgical Oncologists Elicit and Integrate Patient Values.

Journal of surgical oncology·2026

Same journal

A Tale of Two Pathways: Same-Surgeon Versus Different-Surgeon Resection After Second Surgical Opinion.

Journal of surgical oncology·2026

Same journal

How I Do It: The Life and Work of a Rubber Band in Robotic Liver Parenchymal Transection.

Journal of surgical oncology·2026

Same journal

New Paradigms of Cancer Require New Language: A Qualitative Study Exploring Language for Non-Curative Non-Palliative Cancer Surgery.

Journal of surgical oncology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Feb 17, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Systemic therapy in retroperitoneal sarcoma management.

Anastasia Constantinidou¹, Robin L Jones²

¹Medical School University of Cyprus & The BoC Oncology Centre, Nicosia, Cyprus.

Journal of Surgical Oncology

|December 2, 2017

Summary

This summary is machine-generated.

Limited data exists on systemic therapy for retroperitoneal sarcomas. Most subtypes, like liposarcomas and leiomyosarcomas, are chemotherapy-resistant, highlighting the need for better treatments.

Keywords:

adjuvant neoadjuvant palliative retroperitoneal sarcoma systemic therapy

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Related Experiment Videos

Last Updated: Feb 17, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Area of Science:

Oncology
Medical Research

Background:

Retroperitoneal sarcomas lack robust randomized controlled trial data regarding systemic therapy effectiveness.
Current systemic therapy choices are primarily dictated by the specific histological subtype of the sarcoma.

Purpose of the Study:

To highlight the limited evidence for systemic therapy in retroperitoneal sarcomas.
To underscore the need for novel and more effective systemic treatment strategies for these rare tumors.

Main Methods:

Review of existing literature and clinical trial data on systemic therapy for retroperitoneal sarcomas.
Analysis of treatment response based on histological subtypes, including liposarcomas and leiomyosarcomas.

Main Results:

The majority of common retroperitoneal sarcomas, such as liposarcomas and leiomyosarcomas, demonstrate limited sensitivity to conventional chemotherapy.
There is a significant scarcity of high-quality, randomized controlled data evaluating systemic therapies.

Conclusions:

Effective systemic therapies for retroperitoneal sarcomas are urgently required.
Future research should focus on developing novel therapeutic agents and treatment protocols for both early and advanced stages of these challenging cancers.